Xavier and FDA host major pharmaceutical conference that focuses on protecting public health

Challenges include drug shortages and counterfeit drug products | February 21, 2013

Xavier is partnering with the U.S. Food and Drug Administration (FDA) and pharmaceutical manufacturers to present the 2013 FDA/Xavier Pharmalink Conference on campus from March 11-14. The focus of the conference is the protection of public health in light of continuing challenges to the FDA posed by drug shortages and counterfeit drug products.

Congress and the FDA recently addressed these growing concerns by passing legislation to enhance the safety and quality of drugs in the United States. The conference brings together representatives from the FDA Office of the Commissioner and leading companies such as Pfizer, Merck and Eli Lilly to discuss implementation of the new FDA Safety and Innovation Act and how it will impact current manufacturing practices of the pharmaceutical industry.

Featured speakers of the 2013 PharmaLink Conference include John Lechleiter, CEO, president and chairman of Eli Lilly; Steve Solomon, Office of the Commissioner of the FDA; Hussain Mooraj, a partner with Global Lead Life Sciences Supply Chain at Accenture; and Michael Davidson, vice president of Pfizer.

The PharmaLink Conference is part of Xavier’s mission to make a difference in communities served by the University. The conference focuses on maintaining quality in a global pharmaceutical supply chain by creating real solutions for the pharmaceutical industry to put into action. Xavier is collaborating with these experts from the pharmaceutical industry and FDA leaders to foster innovation while upholding the FDA mission to maintain safe, available and affordable drugs for patients in the United States.

More information about the conference and registration are available online. Learn more about Xavier’s health-related academic program offerings, including upcoming conferences, at the Xavier Health website.